Pharmaceuticals News and Research

RSS

BioSpec Global Solutions commences talks with U.K., Chinese distributors for TOGS product lines

ICBS Ltd., announced today that partner BioSpec Global Solutions Inc. has opened talks with a U.K. , and Chinese distributors for the TOGS product lines.

26 Aug 2011

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.

26 Aug 2011

Covidien pledges $375,000 to SIRF's discovery campaign

The Society of Interventional Radiology Foundation's Discovery Campaign, which seeks to further the growth of minimally invasive medicine into new areas of discovery, announced a major corporate pledge to that initiative. Covidien, a manufacturer of medical devices, pharmaceuticals and medical supplies, based in Mansfield, Mass., has pledged $375,000 and is a "Visionary" level supporter.

26 Aug 2011

BioPhausia to sell generics business to Bluefish Pharmaceuticals

Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.

26 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

Roundup: Federal appeals court says Ariz. Medicaid co-pays violate law; Mich. court rules against medicinal marijuana policies

A federal appeals court ruled Wednesday that mandatory copayments charged to Arizona's poorest residents violate federal law. The three-judge panel of the 9th U.S. Circuit Court of Appeals said federal health officials failed to show how the copays, imposed in November after a seven-year court battle, served any purpose besides cutting the state's Medicaid budget.

26 Aug 2011

Simcere receives Chinese SFDA approval for Iremod to treat active rheumatoid arthritis

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has received the new drug approval from the State Food and Drug Administration for Iremod.

25 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

Removal of OTC drugs for toddlers from the market reduces therapeutic errors

A new study by researchers at the University of Maryland has revealed a 46 percent drop in reported errors after drugmakers in October 2007 removed from the market a number of over-the-counter cough and cold medications labeled for children under the age of 2.

25 Aug 2011

Foreign drug manufacturing, testing raise regulatory and ethical concerns

JAMA discusses "a recent report from the Pew Health Group about the growing risks of substandard and counterfeit medications resulting from the increasing overseas production of pharmaceuticals and their ingredients."

25 Aug 2011

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

25 Aug 2011

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

Cortex Pharmaceuticals, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent that protects the use of AMPAKINE molecules for the treatment or prevention of respiratory depression.

25 Aug 2011

Patients with liver disease may now access UCSD's new Nevada clinic

Patients in Nevada seeking care for liver disease may now access the university-level expertise of UC San Diego Health System's Center for Hepatobiliary Disease and Abdominal Transplantation.

25 Aug 2011

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..

24 Aug 2011

DATATRAK announces addition of eClinical Consulting Group to Connect Partner Program

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the newest member of its Connect Partner Program, eClinical Consulting Group.

24 Aug 2011

Par Pharmaceutical enters definitive agreement to acquire Anchen

Par Pharmaceutical Companies, Inc. announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash.

24 Aug 2011

Scientists discover nanoparticles can disrupt intracellular transport pathways

Scientists at the Centre of Cancer Biomedicine at the Norwegian Radium Hospital are the first to show that uptake and accumulation of nanoparticles in cells can disrupt important intracellular transport pathways.

24 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

MedPro Safety Products second quarter net loss decreases to $2.9 million

MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, today reported on several key financial highlights for the second quarter ended June 30, 2011, as well as significant corporate developments.

23 Aug 2011

Pharmaceuticals News and Research

BioSpec Global Solutions commences talks with U.K., Chinese distributors for TOGS product lines

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Covidien pledges $375,000 to SIRF's discovery campaign

BioPhausia to sell generics business to Bluefish Pharmaceuticals

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Roundup: Federal appeals court says Ariz. Medicaid co-pays violate law; Mich. court rules against medicinal marijuana policies

Simcere receives Chinese SFDA approval for Iremod to treat active rheumatoid arthritis

MDxHealth first half 2011 commercial revenues increase 19%

Removal of OTC drugs for toddlers from the market reduces therapeutic errors

Foreign drug manufacturing, testing raise regulatory and ethical concerns

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

Patients with liver disease may now access UCSD's new Nevada clinic

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

DATATRAK announces addition of eClinical Consulting Group to Connect Partner Program

Par Pharmaceutical enters definitive agreement to acquire Anchen

Scientists discover nanoparticles can disrupt intracellular transport pathways

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Trophos awarded US patent covering use of novel cardioprotective compound

MedPro Safety Products second quarter net loss decreases to $2.9 million

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence